The key therapeutic area with the highest potential for partnership and business development in Russia is diseases of the central nervous system (CNS). NovaMedica’s advanced commercial infrastructure, successful history of product licensing and commercialization, experience in cooperation with international companies, as well as our own R&D and manufacturing site will provide a sound bridge for our partners to enter the Russian market.

NovaMedica aims to provide doctors and patients with access to the most innovative and effective pharmaceutical technologies. The NovaMedica portfolio is formed from drugs developed and registered within our own R&D-program (these drugs are manufactored by the R&D-Center NovaMedica Innotech in Moscow) as well as from products from our partners.

R&D Center NovaMedica Innotech was opened in Moscow, it has state-of-the-art technological capacities, carries out research, development and manufacturing of innovative and effective drug products, including on a contractual basis. Production capacity of the R&D Center is up to 150 mln units per year.

For almost ten years, NovaMedica has been using the opportunities of the Russian growing pharmaceutical market to build its portfolio, and invites partners interested in promoting their products in Russia to share in our success.

The key therapeutic area with the highest potential for partnership and business development in Russia is diseases of the central nervous system (CNS). NovaMedica’s advanced commercial infrastructure, successful history of product licensing and commercialization, experience in cooperation with international companies, as well as our own R&D and manufacturing site will provide a sound bridge for our partners to enter the Russian market.

NovaMedica aims to provide doctors and patients with access to the most innovative and effective pharmaceutical technologies. The NovaMedica portfolio is formed from drugs developed and registered within our own R&D-program (these drugs are manufactored by the R&D-Center NovaMedica Innotech in Moscow) as well as from products from our partners.

R&D Center NovaMedica Innotech was opened in Moscow, it has state-of-the-art technological capacities, carries out research, development and manufacturing of innovative and effective drug products, including on a contractual basis. Production capacity of the R&D Center is up to 150 mln units per year.

For almost ten years, NovaMedica has been using the opportunities of the Russian growing pharmaceutical market to build its portfolio, and invites partners interested in promoting their products in Russia to share in our success.